Skip to main content

C-RAD AB: First order for Catalyst in Germany

Press release 2012-04-13

Press release 2012-04-13



A First C-RAD Catalyst System has been ordered by a leading University Clinic in Germany


C-RAD AB with its four fully owned subsidiaries are all active in the field of radiation therapy.  The University Clinic in Aachen has ordered the first Catalyst system in Germany. After a test period the system will be installed at a linac from Elekta.

The Catalyst system is based on a new generation of hardware and software platform for high performance optical surface scanning and augmented reality through re projection. Advanced and highly optimized algorithms for non-rigid registration and deformable models enable the real-time assessment of patient positioning errors before and during treatment delivery. The system is calculating iso center adjustments. Interfaces to major LINAC vendors ensure a completely integrated workflow.

At first the Catalyst system will end of April be installed at a PET CT for a study. Doctor Richard Holy will during a six month period study the correlation between external surface movements and the tumor trajectory. After the study the plan is to move the system to an Electa linac for respiratory gating treatments mainly on patients with lung cancer. The system will be rented. If acquired by the clinic, the rental fee will be deducted.


Erik Hedlund, CEO, C-RAD AB:

”The University Clinic in Aachen is one of the leading radiation therapy centers in Europe. We are happy to announce a first order of Catalyst to a clinic on the important German market. The Catalyst systems is planned to be used for advanced treatments mainly on lung cancer patients. The system will before end of April be installed. C-RAD is looking forward to work with Professor Eble and his group.”


Professor Michael J. Eble, The University Clinic Aachen:

“A high efficacy could be achieved with stereotactic irradiation of lung tumors. Sparing of normal lung tissue correlates to the ability to capture the periodic lung tumor movement, caused by breathing. We are very pleased about the upcoming installation of the C-RAD Catalyst system and appreciate the opportunity for a scientific collaboration to acquire detailed information on the correlation of external surrogates and internal tumor trajectories. Thereafter the system will be implemented in our clinical work- flow for respiration gated stereotactic irradiation of lung cancer, using the new dedicated Elekta Axesse Linac.”



For further information:

Erik Hedlund, CEO C-RAD AB, Phone +46 (0)18  66 69 31, E-mail


Close Menu